2023-Sustainable Industrial Processing Summit
SIPS2023 Volume 5. Guerrant Intl. Symp /Covid-19 and Infectious Diseases
| Editors: | F. Kongoli, F. Murad, W. Petri, H. Inufusa, S. Heysell, J. Yedoyan |
| Publisher: | Flogen Star OUTREACH |
| Publication Year: | 2023 |
| Pages: | 92 pages |
| ISBN: | 978-1-989820-80-3 (CD) |
| ISSN: | 2291-1227 (Metals and Materials Processing in a Clean Environment Series) |
CD shopping page
PRE-CLINICAL AND RANDOMIZED CLINICAL TRIAL WITH BROMHEXINE AND N-ACETYLCYSTEINE FOR COVID-19
Aldo Lima1;1FEDERAL UNIVERSITY OF CEARA, Fortaleza, Brazil;
Type of Paper: Regular
Id Paper: 324
Topic: 68
Abstract:
Treatment options for mild to moderate COVID-19 is limited. N-acetylcysteine and bromhexine have antiviral activity and show potential as treatment options against SARS-CoV-2 infections. This study evaluates the in vitro antiviral effect of bromhexine (BMX) for SARS-CoV-2 and determines the efficacy of treatment with BMX in combination with N-acetylcysteine (NAC) to reduce clinical scores in patients with mild to moderate COVID-19. Upon evidence from pre-clinical studies, a single center randomized trial of BMX + NAC (ClinicalTrials.gov Identifier: NCT04928495) with420 participants in total took place in Fortaleza, CE, Brazil. Out of the 420 participants 140 received placebo, 140 received NAC alone, and 140 received NAC + BMX. Patients were monitored for 10-14 days, where physicians recorded all signs and symptoms reported. Nasopharyngeal swabs and blood samples were collected for SARS-CoV-2 RNA testing during the first visit, as well as 3 and 10 days after. Blood samples were collected at first visit and 10 days after for immuno-inflammatory biomarkers measurements. Treatment with NAC+BMX reduced clinical scores and symptoms when compared to placebo group (2/26; 8% vs 7/18; 39%; p < 0.05). Fever (≥37.8°C) was reduced by NAC + BMX treatment when compared to treatment with NAC alone and placebo. This study was limited by a largely vaccinated population. Our analysis showed that BMX reduces SARS-CoV-2 infection in vitro. Clinical trial results suggested that combinatory treatment with NAC + BMX is beneficial in mild to moderate COVID-19.